Major global pharmaceutical companies have accomplished successful marketing of bispecific antibodies. Now, the Korean biopharmaceutical industry is also joining this challenge. Current bispecific antibodies include Roche’s Lunsumio and Columvi, Abbvie’s Epkinly, and Janssen’s Tecvayli. Korean companies are planning to evaluate the possibility of developing bispecific antibodies in an area of immunotherapy.

According to industry sources on the 26th, Hanmi Pharm, ABL Bio, and ImmuneOncia joined the race to develop bispecific antibodies. Bispecific antibodies are known to have clinical advantages as they have additional specific antigen-binding sites compared to monoclonal antibodies.